Scancell (LON:SCLP) Issues Quarterly Earnings Results

Scancell (LON:SCLP) issued its quarterly earnings results on Thursday. The company reported GBX (0.55) EPS for the quarter, Digital Look Earnings reports.

Scancell Price Performance

Shares of SCLP stock traded down GBX 0.49 during trading hours on Thursday, hitting GBX 12.89. The company’s stock had a trading volume of 2,434,471 shares, compared to its average volume of 2,605,237. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The stock has a market cap of £133.77 million, a price-to-earnings ratio of -10.23 and a beta of 0.35. The business has a fifty day moving average of GBX 10.69 and a 200-day moving average of GBX 10.18. Scancell has a twelve month low of GBX 7.26 and a twelve month high of GBX 14.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.